KD Pharma Buys Rohner Assets
“KD Pharma has all the technology, capacity, and people to become an even larger player in the CDMO market,” said KD Pharma CEO Oscar Groet. “Rohner was known for its unique chemical processes and technological capabilities, enabling it to manufacture difficult, multi-step pharmaceutical intermediates and APIs. This is a natural fit with our strategy to create health solutions and provide value to customers by utilizing a unique toolbox of technologies.”
Rohner was a Swiss-based cGMP contract manufacturer, specializing in rapid scale-up and commercial-scale custom synthesis of complex, small molecule API's, advanced Intermediates and specialty polymers. The company ceased trading in June 2019 because of recurrent environmental problems at the site in Pratteln, which had a knock-on negative impact on the business.
As well as contract manufacturing for pharmaceutical and nutraceutical customers, KD Pharma said it is one of the largest omega-3 fatty acid producers in the world. The company operates sites in Bexbach and Homburg, Germany; Seal Sands, UK; Brattvag, Norway; and Miami, Florida, USA.
Author: Elaine Burridge, Freelance Journalist